INT254308

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 5.12
Pain Relevance 1.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (TNFSF13B) signal transduction (TNFSF13B) extracellular space (TNFSF13B)
extracellular region (TNFSF13B) plasma membrane (TNFSF13B)
Anatomy Link Frequency
B lymphocyte 4
TNFSF13B (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 4 98.20 Very High Very High Very High
Inflammation 42 98.00 Very High Very High Very High
rheumatoid arthritis 140 97.20 Very High Very High Very High
cytokine 42 89.96 High High
chemokine 5 89.40 High High
antagonist 15 72.68 Quite High
abatacept 3 67.68 Quite High
methotrexate 89 48.64 Quite Low
Central nervous system 7 36.88 Quite Low
Arthritis 10 35.44 Quite Low
Disease Link Frequency Relevance Heat
Apoptosis 22 99.56 Very High Very High Very High
Systemic Lupus Erythematosus 379 98.16 Very High Very High Very High
INFLAMMATION 42 98.00 Very High Very High Very High
Rheumatoid Arthritis 140 97.20 Very High Very High Very High
Hyperplasia 6 95.32 Very High Very High Very High
Vasculitis 60 92.16 High High
Disease 232 91.68 High High
Lymphatic System Cancer 16 82.00 Quite High
Congenital Anomalies 26 78.88 Quite High
Autoimmune Disease 30 75.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Agents blocking these components in addition to BlyS (or inhibiting membrane BlyS in addition to soluble BlyS) are being studied.
Negative_regulation (inhibiting) of BlyS
1) Confidence 0.42 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 0.41 Pain Relevance 0
Belimumab inhibits soluble BLyS activity at subnanomolar concentrations in a murine model [19].
Negative_regulation (inhibits) of BLyS
2) Confidence 0.42 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592791 Disease Relevance 0.32 Pain Relevance 0.12
A novel B cell targeted approach, via inhibition of BlyS, has shown early promise in the treatment of SLE.
Negative_regulation (inhibition) of BlyS in B cell associated with systemic lupus erythematosus
3) Confidence 0.38 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 0.56 Pain Relevance 0.08
This is consistent with the ability of belimumab to inhibit BLyS biologic activity.
Negative_regulation (inhibit) of BLyS
4) Confidence 0.37 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592791 Disease Relevance 0.20 Pain Relevance 0.04
B lymphocyte stimulator inhibition: belimumab
Negative_regulation (inhibition) of B lymphocyte stimulator in B lymphocyte
5) Confidence 0.33 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 0.40 Pain Relevance 0.27
Agents blocking these components in addition to BlyS (or inhibiting membrane BlyS in addition to soluble BlyS) are being studied.
Negative_regulation (inhibiting) of BlyS
6) Confidence 0.31 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 0.42 Pain Relevance 0
These effects were believed to be related to apoptosis induced by prolonged BLyS depletion and were reversible within 5 months of drug withdrawal.
Negative_regulation (depletion) of BLyS associated with apoptosis and withdrawal
7) Confidence 0.27 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592791 Disease Relevance 0.30 Pain Relevance 0.08
Furie and coworkers [3] conducted a phase I investigation of belimumab (LymphoStat-B, Human Genbome Sciences Inc., Rockville, MD, USA), a fully human monoclonal antibody that inhibits soluble BLyS.
Negative_regulation (inhibits) of BLyS
8) Confidence 0.25 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 0.63 Pain Relevance 0.18
The investigators concluded that there was a significant reduction in peripheral B cells with LymphoStat-B treatment, consistent awith its ability to bind and inhibit the biological activity of BLyS.


Negative_regulation (inhibit) of BLyS in B cells
9) Confidence 0.25 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 0.60 Pain Relevance 0.03
Therapies that inhibit BLyS currently under development include soluble receptors such as TACI-Ig and anti-BLyS monoclonal antibodies.
Negative_regulation (inhibit) of BLyS
10) Confidence 0.25 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 0.44 Pain Relevance 0.26
Atacicept is a recombinant fusion protein which blocks both BLyS and APRIL by blocking their receptor TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and has been used in SLE and rheumatoid arthritis.88 The role of these B-cell modulating agents in AAV remains to be explored.
Negative_regulation (blocks) of BLyS in B-cell associated with rheumatoid arthritis, vasculitis and systemic lupus erythematosus
11) Confidence 0.06 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2893757 Disease Relevance 0.84 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox